Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

Anyone who's been prescribed a GLP-1 drug like Ozempic, Wegovy or Trulicity to treat type 2 diabetes or help them lose weight ...

Medicare Part D and some Medicare Advantage (Part C) plans may cover Trulicity for managing type 2 diabetes, but coverage specifics depend on the plan’s formulary (drug list). Medicare typically does ...

The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

Eli Lilly has put the flesh on the bones of its REWIND cardiovascular outcomes study for diabetes drug Trulicity, a key element in its defence against a rival drug from Novo Nordisk. All told, there ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

News 8 On Your Side is investigating a critical drug shortage frustrating diabetics who need the medicine.Investigator Susan Shapiro looked into the shortage and what the drug maker had to say about ...

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received ...

Novo Nordisk has announced new data showing that its once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist Ozempic provided greater weight reductions than Eli Lilly’s rival drug Trulicity in ...